Navigation Links
Combination of 2 drugs reverses liver tumors
Date:5/2/2012

The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute (IDIBELL). The study results are been published on the online edition of the journal Science Translational Medicine.

Primary liver cancer or hepatocellular carcinoma is the fifth most common cancer and, due to its aggressiveness, is the third most deadly. It affects half a million people worldwide. Two of every three cases are related to chronic alcoholism, the exposure of toxic agents or infection with hepatitis B or C. The remaining third is related to non-alcoholic steatohepatitis, a disease related to obesity.

Promising candidates

Currently, the antitumor sorafenib shows the better patient outcomes, but its effectiveness decreases over time. For this reason, it is necessary to find new therapies. Among the most promising candidates are the inhibitors of the mTOR signalling pathway, which is hyperactivated in half of those affected by hepatocellular carcinoma.

The study led by IDIBELL researchers compared the effects in mice of two inhibitors of mTOR. The first was a derivative of rapamycin, called everolimus (RAD001), which is already used as an immunosuppressant and to treat specific cancers. The second is a new generation drug that inhibits mTOR called BEZ235.

During the study, researchers found unexpectedly that the combination of the two drugs had a more potent effect than any of the two drugs separately. Coadministration of BEZ235 and RAD001 limits the development of tumour and causes the self-destruction of tumour cells.

Based on these results a clinical trial, funded by Novartis, has started in the United States to evaluate the efficacy of the combination of these two inhibitors of mTOR in humans. The study coordinator, Sara Kozma, noted that "because rapamycin and its derivatives are already approved for the treatment of other diseases, their combination to BEZ235, would be a rapid strategy to test the efficacy of this drug and fast track its approval for clinical use."

Metabolism and Cancer Group

Dr. Kozma has recently joined the IDIBELL, along with Dr. George Thomas, who also participated in the study. The researchers, coming from the University of Cincinnati, have launched a new group of Metabolism and Cancer in IDIBELL.

The study published in Science Translational Medicine has been conducted in the University of Cincinnati, in collaboration with the Center for Cancer Research National Cancer Institute U.S. medical school at the University of California, Los Angeles, Cincinnati Children 's Hospital Medical Center and research institutes of Novartis.


'/>"/>

Contact: Jordi Morato
jmorato@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Related medicine news :

1. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
2. Combination therapy more effective for enlarged prostate
3. Combination Treatment May Help Depressed Alcoholics
4. Researchers find new chemotherapy combination shows promise in endometrial cancer
5. Leeza Gibbons and ZERONA Equals a Winning Combination
6. Combination antibiotics effective against chlamydia-induced arthritis
7. Hair Loss Doctor Overcomes Odds To Produce First Ever Combination Topical Hair Growth Formula
8. Combination therapy targets stubborn leukemia stem cells
9. Combination treatment regimen not effective against advanced melanoma
10. New combination effective against pancreatic cancer
11. Noninvasive combination technique may reduce number of breast biopsies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , ... May 24, 2016 , ... Mental health watchdog ... the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its ... “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has ... and expanded Children’s Hospital. Over 3,000 people looked on as the shovels hit the ... event photo slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... the perfect data logger for each job, ensuring the best suited solution to ... of MadgeTech data loggers at their lab in Istanbul. , Metroloji Okulu specializes ...
(Date:5/24/2016)... ... 2016 , ... Growing in popularity, more and more people continue to live ... easily accessible. Whether someone chooses to cut gluten out of their life for personal ... Grocery stocks their shelves with many different gluten-free products all year round. And they ...
(Date:5/24/2016)... ... May 24, 2016 , ... The number of health insurance ... 10% over last year, according to data in the forthcoming AIS’s Directory of ... stable, with a slight decrease in risk-based groups and a slight increase in ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 ... , la première endoprothèse à double ... à l,intervention portant sur les membres inférieurs ... OrbusNeich, entreprise mondiale spécialisée dans la ... la vie, a élargi son portefeuille pour ...
(Date:5/24/2016)... -- Dutch surgeons have launched a ground-breaking medical app ... treat patients on a global scale. Medical professionals from ... and the US have already signed up for the ... a totally secure environment. Education  "Imagine a ... with a surgeon at Harvard to treat a bomb victim via ...
(Date:5/23/2016)... 23, 2016 According to ... Market by Product (Wheelchair, Scooters, Medical Beds, Bathroom ... Critical Care, Wound), Accessories (Lifting, Transfer) & by ... published by MarketsandMarkets, the patient handling equipment market ... 2021 at a CAGR of 10.5% during the ...
Breaking Medicine Technology: